Formulations and methods for treating dermatological disorders and diseases

1. A method of treating a dermatological disorder or disease in a subject in need thereof,

wherein said method comprises administering to said subject a pharmaceutically acceptable composition,

wherein said composition comprises a pharmaceutically acceptable excipient and at least one component selected from the group consisting of:

(a) a metered amount of a volatile anesthetic dissolved in a solution in an amount effective to treat said dermatological disorder or disease, wherein said solution further comprises at least one extractive solvent in an amount effective to reduce volatility of said volatile anesthetic, wherein said solution is a component of an emulsion;

(b) a metered amount of a liposome suspension comprising a volatile anesthetic in an amount effective to treat said dermatological disorder or disease;

(c) a metered amount of a volatile anesthetic dissolved in a solution in an amount effective to treat said dermatological disorder or disease, wherein said solution further comprises at least one extractive solvent in an amount effective to reduce volatility of said volatile anesthetic, wherein said composition further comprises a solubilizing agent;

(d) a metered amount of a micro-droplet suspension, wherein said micro-droplet suspension comprises a sphere of a volatile anesthetic in an amount effective to treat said dermatological disorder or disease, wherein said sphere is surrounded by a stabilizing layer of a phospholipid;

and any combinations thereof,

wherein said volatile anesthetic is selected from the group consisting of isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, and any mixtures thereof;

wherein said dermatological disorder or disease is selected from the group consisting of itching, dry skin, sunburn, scab healing, scar growth, and any combinations thereof,

whereby said dermatological disorder or disease in said subject is treated.

2. The method of claim 1 , wherein said at least one extractive solvent is selected from the group consisting of dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), dimethylformamide, dimethylacetamide, dimethylisosorbide, ethanol, propanol, PEG-400, PEG-300, diethylene glycol monoethyl ether, isopropanol, and any combinations thereof.

3. The method of claim 1 , wherein said administering is performed by a route selected from the group consisting of topical, transdermal, mucosal, rectal, vaginal, and any combinations thereof.